secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001437749-24-016275
Event type: other_material
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics shareholders reject amendments to 2014 Equity Incentive Plan at annual meeting
--------------------------------------------------------------------------------

- Three Class III directors elected: Thomas D. Anderson, Neil F. McFarlane, Alvin Shih, M.D.
- Shareholders ratified Ernst & Young LLP as independent auditor for FY2024.
- Advisory say-on-pay vote approved (11.2M for, 9.9M against).
- Proposal to amend 2014 Equity Incentive Plan failed: 4.1M for, 17.0M against, 9.9M broker non-votes.
- Approximately 74.5% of shares represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/0001437749-24-016275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924016275/zvra20240513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer